The First Results of Ruxolitinib Versus Best Available Therapy for Polycythemia Vera in Mongolia

被引:0
作者
Gonchigdash, Chinbat [1 ]
Purevsuren, Baljinnyam [1 ]
Tungalag, Saruul [1 ]
Tungalagchimeg, Erdenechimeg [1 ]
Norov, Oyundelger [1 ]
机构
[1] First Cent Hosp Mongolia, Ulaanbaatar, Mongolia
关键词
MPN; ruxolitinib; polycythemia vera; hydroxyurea;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MPN-374
引用
收藏
页码:S430 / S430
页数:1
相关论文
共 34 条
  • [31] Ruxolitinib Combined with Corticosteroids as First-Line Therapy for Acute Graft-versus-Host Disease in Haploidentical Peripheral Blood Stem Cell Transplantation Recipients
    Hou, Cheng
    Dou, Liping
    Jia, Mingyu
    Li, Fei
    Wang, Shuhong
    Gao, Xiaoning
    Wang, Lu
    Jin, Xiangshu
    Wang, Lijun
    Gao, Chunji
    Liu, Daihong
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (01): : 75.e1 - 75.e10
  • [32] Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial
    Dou, Liping
    Peng, Bo
    Li, Xin
    Wang, Lu
    Jia, Mingyu
    Xu, Lingmin
    Li, Fei
    Liu, Daihong
    TRIALS, 2022, 23 (01)
  • [33] Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial
    Liping Dou
    Bo Peng
    Xin Li
    Lu Wang
    Mingyu Jia
    Lingmin Xu
    Fei Li
    Daihong Liu
    Trials, 23
  • [34] Overall Survival (OS) and Progression-Free Survival (PFS) in Patients Treated with Fedratinib as First-Line Myelofibrosis (MF) Therapy and after Prior Ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 Trials
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    Vannucchi, Alessandro
    Mesa, Ruben
    Reiter, Andreas
    Zhang, Jun
    Rose, Shelonitda
    Mascarenhas, John
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S356 - S356